Evidence map›Paper›PMID 40568248›Full record

ArticleNeuroimage. Reports2022

Cross-sectional and longitudinal Biomarker extraction and analysis for multicentre FLAIR brain MRI.

J DiGregorio, A Gibicar, H Khosravani, P Jabehdar Maralani, J-C Tardif, P N Tyrrell, A R Moody, A Khademi

Abstract read
In one paragraph

Article in Neuroimage. Reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Brain Age Estimation on a Dementia Cohort Using FLAIR MRI Biomarkers.AJNR. American journal of neuroradiology · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J DiGregorioElectrical, Computer and Biomedical Engineering Dept., Ryerson University, Toronto, ON, Canada.
A GibicarElectrical, Computer and Biomedical Engineering Dept., Ryerson University, Toronto, ON, Canada.
H KhosravaniDivision of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
P Jabehdar MaralaniDepartment of Medical Imaging, University of Toronto, Toronto, ON, Canada.
J-C TardifMontreal Heart Institute, Montreal, QU, Canada.
P N TyrrellDepartment of Statistical Science, University of Toronto, Toronto, ON, Canada.
A R MoodyDepartment of Medical Imaging, University of Toronto, Toronto, ON, Canada.
A KhademiElectrical, Computer and Biomedical Engineering Dept., Ryerson University, Toronto, ON, Canada.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Fluid-attenuated inversion recovery (FLAIR) MRI has emerged as an important sequence for the analysis of cerebrovascular (CVD) and Alzheimer's disease (AD). Large-scale, automated cross-sectional and longitudinal cerebral biomarker extraction from FLAIR datasets could progress disease characterization, improve disease monitoring, and help to determine optimal intervention times. Despite this, most automated biomarker extraction algorithms are designed for T1-weighted or multi-modal inputs. In this work, automated tools were used to extract biomarkers from large, FLAIR-only datasets to evaluate the feasibility of this sequence to characterize healthy, AD, and CVD subjects in a similar manner to traditional approaches. Total brain volume (TBV), cerebrospinal fluid (CSF) volume, and white matter lesion (WML) volume was measured for the cross-sectional biomarkers and the corresponding annual rates of change over multiple scans represented the longitudinal biomarkers. Biomarkers were extracted from two dementia cohorts (4356 vol, 162 233 images) and one vascular disease cohort (869 vol, 42 850 images) using deep learning-based segmentation algorithms designed specifically for FLAIR. Biomarkers from all cohorts were summarized using descriptive statistics, correlation analysis, and ANCOVA to assess differences in diagnostic labels while accounting for demographic and acquisition factors. Biomarkers from FLAIR MRI had similar trends with those extracted from traditional modalities in the literature for characterizing healthy, AD, and CVD subjects. This demonstrates that FLAIR MRI can be used for end-to-end analysis of large AD and CVD datasets, which can lower acquisition costs, simplify clinical translation, and reduce measurement error associated with multi-modal approaches.

Indexed as

Alzheimer's diseaseCerebral biomarkersCerebrovascular diseaseFLAIR MRI

Identifiers

PMID40568248
PMCPMC12172794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.